Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15045956rdf:typepubmed:Citationlld:pubmed
pubmed-article:15045956lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:15045956lifeskim:mentionsumls-concept:C0262950lld:lifeskim
pubmed-article:15045956lifeskim:mentionsumls-concept:C0032231lld:lifeskim
pubmed-article:15045956lifeskim:mentionsumls-concept:C0227375lld:lifeskim
pubmed-article:15045956lifeskim:mentionsumls-concept:C0007102lld:lifeskim
pubmed-article:15045956lifeskim:mentionsumls-concept:C0494165lld:lifeskim
pubmed-article:15045956lifeskim:mentionsumls-concept:C0439064lld:lifeskim
pubmed-article:15045956lifeskim:mentionsumls-concept:C1709059lld:lifeskim
pubmed-article:15045956lifeskim:mentionsumls-concept:C0201734lld:lifeskim
pubmed-article:15045956lifeskim:mentionsumls-concept:C0205250lld:lifeskim
pubmed-article:15045956lifeskim:mentionsumls-concept:C1533148lld:lifeskim
pubmed-article:15045956lifeskim:mentionsumls-concept:C0332293lld:lifeskim
pubmed-article:15045956lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:15045956lifeskim:mentionsumls-concept:C0701185lld:lifeskim
pubmed-article:15045956pubmed:issue3lld:pubmed
pubmed-article:15045956pubmed:dateCreated2004-3-29lld:pubmed
pubmed-article:15045956pubmed:abstractTextA 54 year-old male was admitted for highly advanced ascending colon cancer with multiple bone and liver metastases and pleuritis carcinomatosa. He was treated with pharmacokinetic modulating chemotherapy (PMC) and low-dose CPT-11. UFT (400 mg) was orally administered daily and a 2-hour infusion of l-leucovorin (250 mg/m2/day) with a continuous infusion of 5-FU (600 mg/m2/24 h) was given once a week on an outpatient basis. CPT-11 (80 mg/body/2 h) was administered every 2 weeks. Partial response was obtained in the liver for 6 months and in the primary lesion for 9 months. Significant decrease of pain from the multiple bone metastases was observed for 4 months without severe side effects, which led to an improvement in performance status and quality of life for the patient. He survived more than 11 months after initial treatment. The duration of his stay at home was 288 days, accounting for 83% of the treatment period. This case suggests the efficacy of home anticancer therapy with PMC and low-dose CPT-11 for highly advanced colon cancer in terms of QOL.lld:pubmed
pubmed-article:15045956pubmed:languagejpnlld:pubmed
pubmed-article:15045956pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15045956pubmed:citationSubsetIMlld:pubmed
pubmed-article:15045956pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15045956pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15045956pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15045956pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15045956pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15045956pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15045956pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15045956pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15045956pubmed:statusMEDLINElld:pubmed
pubmed-article:15045956pubmed:monthMarlld:pubmed
pubmed-article:15045956pubmed:issn0385-0684lld:pubmed
pubmed-article:15045956pubmed:authorpubmed-author:WatanabeYoshi...lld:pubmed
pubmed-article:15045956pubmed:authorpubmed-author:YagyuToshihik...lld:pubmed
pubmed-article:15045956pubmed:authorpubmed-author:AiharaTsukasa...lld:pubmed
pubmed-article:15045956pubmed:authorpubmed-author:MurayamaMichi...lld:pubmed
pubmed-article:15045956pubmed:authorpubmed-author:NakamuraEisyu...lld:pubmed
pubmed-article:15045956pubmed:authorpubmed-author:NozakiHidetoHlld:pubmed
pubmed-article:15045956pubmed:authorpubmed-author:NiidaMasakuni...lld:pubmed
pubmed-article:15045956pubmed:authorpubmed-author:YasuokaHiroki...lld:pubmed
pubmed-article:15045956pubmed:authorpubmed-author:NishimotoYuta...lld:pubmed
pubmed-article:15045956pubmed:authorpubmed-author:SyoudaShinich...lld:pubmed
pubmed-article:15045956pubmed:authorpubmed-author:KounoToshihik...lld:pubmed
pubmed-article:15045956pubmed:authorpubmed-author:FukuharaAkino...lld:pubmed
pubmed-article:15045956pubmed:authorpubmed-author:NakagawaKatsu...lld:pubmed
pubmed-article:15045956pubmed:issnTypePrintlld:pubmed
pubmed-article:15045956pubmed:volume31lld:pubmed
pubmed-article:15045956pubmed:ownerNLMlld:pubmed
pubmed-article:15045956pubmed:authorsCompleteYlld:pubmed
pubmed-article:15045956pubmed:pagination431-3lld:pubmed
pubmed-article:15045956pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:15045956pubmed:meshHeadingpubmed-meshheading:15045956...lld:pubmed
pubmed-article:15045956pubmed:meshHeadingpubmed-meshheading:15045956...lld:pubmed
pubmed-article:15045956pubmed:meshHeadingpubmed-meshheading:15045956...lld:pubmed
pubmed-article:15045956pubmed:meshHeadingpubmed-meshheading:15045956...lld:pubmed
pubmed-article:15045956pubmed:meshHeadingpubmed-meshheading:15045956...lld:pubmed
pubmed-article:15045956pubmed:meshHeadingpubmed-meshheading:15045956...lld:pubmed
pubmed-article:15045956pubmed:meshHeadingpubmed-meshheading:15045956...lld:pubmed
pubmed-article:15045956pubmed:meshHeadingpubmed-meshheading:15045956...lld:pubmed
pubmed-article:15045956pubmed:meshHeadingpubmed-meshheading:15045956...lld:pubmed
pubmed-article:15045956pubmed:meshHeadingpubmed-meshheading:15045956...lld:pubmed
pubmed-article:15045956pubmed:meshHeadingpubmed-meshheading:15045956...lld:pubmed
pubmed-article:15045956pubmed:meshHeadingpubmed-meshheading:15045956...lld:pubmed
pubmed-article:15045956pubmed:meshHeadingpubmed-meshheading:15045956...lld:pubmed
pubmed-article:15045956pubmed:meshHeadingpubmed-meshheading:15045956...lld:pubmed
pubmed-article:15045956pubmed:meshHeadingpubmed-meshheading:15045956...lld:pubmed
pubmed-article:15045956pubmed:meshHeadingpubmed-meshheading:15045956...lld:pubmed
pubmed-article:15045956pubmed:meshHeadingpubmed-meshheading:15045956...lld:pubmed
pubmed-article:15045956pubmed:meshHeadingpubmed-meshheading:15045956...lld:pubmed
pubmed-article:15045956pubmed:year2004lld:pubmed
pubmed-article:15045956pubmed:articleTitle[A case of highly advanced ascending colon cancer with multiple bone and liver metastases and pleuritis carcinomatosa treated with pharmacokinetic modulating chemotherapy and low-dose CPT-11].lld:pubmed
pubmed-article:15045956pubmed:affiliationDept. of Surgery, Japan Self Defense Force Hanshin Hospital.lld:pubmed
pubmed-article:15045956pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15045956pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:15045956pubmed:publicationTypeCase Reportslld:pubmed